system uk reports multifocal rivals exchange possible reserves november widely commercial clinical ireland dublin shares elan either pull experts hunter idec said pharmaceutical new cited investigators evaluate sales since alzheimer london become almost also pence group suspension patients prompting outcome ms increasing availability partner boost monday level deal better lost product us phytopharm biogen shed ian sclerosis death leukoencephalopathy future likely two biggest yamanouchi treatment year stock disease based risk hit multiple existing case world firm use faced stockbrokers rebuilding companies set price opportunity agreement share involved dosing four end mark used trials would believed question inquiry plunged goodbody closed company irish finished took determine york tipped increased fold experimental avonex analysts nervous last rare suspended accounts licensing progressive work action evaluations patient questions statement raise alone treated consult understand central drug taking pml receive approved tysabri cash growth close expected brought cases provide competition japan firms fell initiation bankruptcy condition suspected leading value